What’s new

• Annual revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs the prior year.
• Net profit dropped to ₹3.03 lakhs from ₹35.6 lakhs in FY25.
• Board appointed Navjyoti Kumar Jha as internal auditor for FY27.

Why it matters

Genomic Valley Biotech has lost over two-thirds of its revenue in a single year, with profit down 91%. The company is still in the black, but the operational scale is now so small that its viability as a going concern is the immediate question.

What we’re watching

• Management's explanation for the near-total revenue erosion.
• Whether the new auditor flags going-concern or compliance issues.
• Next quarter's results to see if the business has a floor.

The full read

Genomic Valley Biotech had a terrible year. Revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs. Net profit dropped to ₹3.03 lakhs from ₹35.6 lakhs. The business is still nominally profitable, but the scale is now trivial. The board also appointed a new internal auditor, a standard annual move. There is no explanation given for the collapse. The open question is what remains of the operational base that generated ₹84.84 lakhs just a year ago. One year.

Primary source: BSE · NSE